Level Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Level Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-75	Closed	–	–	346
2022 Q2	$0	Buy	+75	New	+$186	﹤0.01%	351

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Level Financial Advisors's VKTX Position: Q3 2022 in Review

Level Financial Advisors sold out of Viking Therapeutics (VKTX) in Q3 2022, closing a stake of 75 shares.

Level Financial Advisors first reported a position in VKTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 107 funds tracked by Wall St. Rank hold VKTX as of Q3 2022.

Level Financial Advisors reported no remaining Viking Therapeutics position as of Q3 2022 after selling out during the quarter.
Level Financial Advisors sold 75 Viking Therapeutics shares in Q3 2022.
Level Financial Advisors first reported a position in Viking Therapeutics in Q2 2022 and held it in 1 quarter.
Level Financial Advisors's Viking Therapeutics position peaked at $0 in Q2 2022.
107 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2022.

Based on Level Financial Advisors's 13F filing for Q3 2022, filed 18 Oct 2022.